紫杉醇脂质体对比吉西他滨联合顺铂一线治疗中晚期肺鳞癌的疗效评价.docVIP

紫杉醇脂质体对比吉西他滨联合顺钳一线治疗中晚期肺鳞癌的疗效评价 杨另争翔，罗虎，周向东(400038重庆，第三军医大学第一附属医院呼吸内科) ［摘魁目的 对比紫杉醇脂质体联合顺钳方案(LP)与吉西他滨联合顺钳方案(GP) 一线治疗III/IV期肺鳞癌的 临床疗效、毒副作用及远期预后。方法 共纳入71例III/IV期鳞癌患者，LP组37例，GP组34例，分别给予注射用紫 杉醇脂质体(175mg/nr) +顺￡白(75mg/nr)和注射用吉西他滨(1000mg/m)+顺￡白(75mg/m2)治疗，21夭为I个周期； 2个周期化疗结束后系统评价英疗效。结果 对于肺原发灶两组客观缓解率(37.8% 32.4%,P=0.629)和疾病控制率(83.8% V5 76.5%, P=0.439)无统计学差异；对于区域转移的淋巴结两组客观缓解率(45.9% w 20.6%, P二0.024)和疾病控制率(86.5% 64.7%,P=0.032)均为LP组显著增髙。LP组无疾病进展生存期高于GP组(7.0月佑5.0月,P=0.014)。LP化疗组血小 板减少、恶心及呕吐发生率低于GP化疗组(PV0.05)。结论对于伴有区域淋巴结转移的鳞癌患者，LP方案毒副作 用更少，可获得更高的无疾病进展生存期，可能更能使患者获益。 ［关键词］紫杉醇脂质体；吉西他滨；肺癌；化疗 Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for advanced squamous lung cancer Yang Jingxiang, Luo Hu. Zhou Xiangdong(Dcpartmcnt of Respiratory Medicine, the First Affiliated Hospital of Third Military Medical University, Chongqing 400038,China) Correspondence to： Zhou Xiangdong Email:xiangdongzhou@ 126.com lAbstractJ Objective: To compare the effect and safety for Paclitaxel liposome plus cisplatin(LP) or gemcitabine and cisplatin(GP) in advanced lung squamous cell carcinoma (SCC) with regional lymph node metastasis Methods: 71 advanced lung SCC were assigned to receive either liposomal paclitaxel (175mg/m2) and cisplatin (75mg/nr) or gcmcitabinc( 1 OOOmg/nr) and cisplatin (75mg/m2) every 3 weeks? All patients were treated with at least two 21 -day courses, and evaluated by chest CT every two courses. ResultszNo statistical di fl ere nee were observed between the LP and GP groups in terms of objective response rate (ORR) of lung primary foci (37.8% vs 32.4%, P=0.629) and the disease control rate(DCR) of lung primary foci(86.5% v.v 64.7%, P=0.439);LP had higher ORR of regional metastasis lymph node( 45.9% vs 20.6%, P二0.024) and DCR of regional metastasis lymph nodc(86.5% vs 64.7%, P=0?032)? Longer progression free survival(PFS) was observed in LP groups(7.0 vs 5.0 inonihs, P=0.014). LP was associated with significantly les